
Selvita S.A.
Research and experimental development in natural sciences and engineering
Overview
Selvita is an integrated service provider specializing in drug discovery and drug development. It offers comprehensive services from target validation to preclinical candidate nomination, supporting small molecules, antibodies, and protein degraders, along with extensive drug development and regulatory support for both small and large molecules. The company adheres to GMP and GLP regulations, ensuring scientific consistency and global compliance throughout the development process.
Financials
Revenue history (in m)
Filing timeliness
Financial statements were filed on time, on average 10 days early. All were audited by a statutory auditor.
- 202530/06/2026
- 202410/07/2025
- 202328/06/2024
- 202212/07/2023
- 202114/07/2022
- 202029/09/2021
The statements for 2025 report only zeros (no activity).
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Stock quotes
- Open
- PLN 17.28
- High
- PLN 17.30
- Low
- PLN 16.52
- Volume
- 21.66K
- Avg. vol.
- 36.91K
- Market cap
- PLN 308.74M
- P/E ratio
- –
- EPS
- -PLN 0.11
- Shares outstanding
- 18.36M
- 52-week
- PLN 15.56 – 18.34
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLSLVCR00029
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 22.19m | USD -183.95k | USD -821.45k |
| Q1 2026 | USD 20.52m | USD -482.44k | USD -1.47m |
| Q4 2025 | USD 23.26m | USD 2.11m | USD 1.84m |
| Q3 2025 | USD 22.12m | USD 572.58k | USD -235.06k |
Results for Q3 2026:Nov 19, 2026
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Public procurement
1 tender recorded as contractor, with a total value of $13,687.
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Apr 7, 2025 | 459.2024 Selection of a contractor to consult on the content of course syllabi for the Faculty of Chemistry, divided into six lots. | $13,687$13,687 | Uniwersytet Jagielloński |
The company is the contractor in one public sector contract, worth USD 7.54k.
| Signed on | Subject | Amount | Public buyer | |
|---|---|---|---|---|
| Jul 28, 2026 | Purchase of antibodies for molecular biology | $7,536 | Warszawski Uniwersytet Medyczny |
Selvita has been a party to 2 cases before the National Appeal Chamber (since 2011).
| Date | Subject of dispute | Outcome | Other party | |
|---|---|---|---|---|
| Sep 16, 2011 | Conditions for participation in the procedure | Upheld | Instytut Nafty i Gazu w Krakowie | |
| Sep 16, 2011 | Non-compliance with the contract terms | Upheld | Instytut Nafty i Gazu w Krakowie |
Authorized Representatives
Manner of representation
In the case of a multi-member management board, the company may be represented by two members of the management board acting jointly, or by a member of the management board acting jointly with one of the joint commercial proxies.
Supervisory board
Beneficial owners
Selvita is a public company listed on the Warsaw Stock Exchange, so it does not report beneficial owners to the CRBR (Art. 58 of the Polish AML Act). Its shareholders are disclosed in stock-exchange reports.
Capital group
| Name | Ownership |
|---|---|
Aktywa netto p rzypadające n a Selvita S.A. | 74% |
Selvita Inc | 100% |
Selvita Ltd | 100% |
Bank accounts
Registered as a VAT taxpayer on 2019-08-09.
69 1020 2892 0000 5602 0716 1690
11 1240 6292 1111 0011 1212 5674
94 1240 6292 1111 0011 0708 3187
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
6 notices recorded in the Court and Commercial Gazette (MSiG).
| Publication date | Event | |
|---|---|---|
| Jun 2, 2020 | Commercial Companies Code notice | |
| Jun 2, 2020 | Commercial Companies Code notice | |
| Oct 14, 2019 | Merger registered | |
| Oct 14, 2019 | Call to creditors | |
| Jul 24, 2019 | Merger registered |
Public aid
19 public aid cases recorded, with a total value of $45,055,001.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 27, 2026 | Regional investment aid | –– | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Mar 27, 2026 | Aid for research and development projects: industrial research | –– | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Mar 27, 2026 | Aid for research and development projects: experimental development | –– | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
8 projects co-financed from European Funds recorded, with total EU co-financing of $35,260,216.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2026-01-01 | Development of DRUG-PREDICT technology for preclinical prediction of the clinical efficacy of biologically active compounds for colorectal and pancreatic cancer indications, based on translational preclinical in vitro and in vivo models supported by an ML tool, enabling the identification of the best innovative drug candidates and optimal patient groups | $3.5M$3,490,265 | European Funds for a Modern Economy | |
| 2026-01-01 | Advanced E3Explorer platform for the production of E3 ligase proteins, together with their characterization, as the basis for innovative PROTAC targeted therapies | $2.3M$2,325,809 | European Funds for a Modern Economy | |
| 2025-10-01 | CART-AI platform for developing advanced immuno-oncology therapies based on modified T lymphocytes using AI – preclinical stage | $2.5M$2,519,767 | European Funds for a Modern Economy |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| Waste generation | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Roche Polska sp. z o.o. | $799,694,562.77 | roche.pl | ||
| Sciencepharma sp. z o.o. | $111,783,976.52 | sciencepharma.com | ||
| Narodowe Centrum Badań Jądrowych Research institute | $107,421,404.09 | ncbj.gov.pl | ||
| Instytut Matki i Dziecka Research institute | $96,646,105.47 | imid.med.pl | ||
| Iqvia Solutions Poland sp. z o.o. | $78,608,834.52 | iqvia.com | ||
| PPD Poland sp. z o.o. | $59,538,223.87 | ppd.com | ||
| KCR S.A. | $43,596,034.97 | kcrcro.com | ||
| Pratia S.A. | $28,984,298.31 | pratia.com | ||
| Sieć Badawcza Łukasiewicz - Instytut Mikroelektroniki i Fotoniki Research institute | $27,889,300.52 | imif.lukasiewicz.gov.pl | ||
| Sieć Badawcza Łukasiewicz - Port Polski Ośrodek Rozwoju Technologii Research institute | $24,232,583.73 | port.lukasiewicz.gov.pl |
Change history
| Date | Event | |
|---|---|---|
| 2023-05-31 | Address change (Ul. Profesora Michała Bobrzyńskiego 14, 30-348, Kraków → Ul. Podole 79, 30-394, Kraków) | |
| 2020-06-18 | Share capital increase (12,776,983.20 PLN → 14,684,379.20 PLN) | |
| 2020-02-14 | Share capital reduction (12,876,983.20 PLN → 12,776,983.20 PLN) | |
| 2019-10-01 | Share capital increase (100,000.00 PLN → 12,876,983.20 PLN) | |
| 2019-10-01 | Name change (Selvita Cro → Selvita) |
FAQ
Last updated: 2026-10-08